Other languages Genetic Signatures Limited

Equities

GSS

AU000000GSS4

Market Closed - Australian S.E. Other stock markets 06:58:37 26/06/2024 BST			5-day change	1st Jan Change
0.71 ^AUD	-0.70%		0.00%	+63.22%

06-04	Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen? Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US	CI
06-04	Genetic Signatures Launches AU$30 Million Equity Raising	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen? Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US	06-04
Genetic Signatures Appoints Interim CEO	04-30
Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-21
Genetic Signatures Completes Rights Issue	01-24
Genetic Signatures Closes AU$8 Million Placement	12-29
Genetic Signatures Limited Appoints Stephane Chatonsky as Director	12-04
Genetic Signatures Submits 510(k) Application to the US FDA to Market Parasite Detection Kit in the US; Shares Jump 17%	04/09/23
Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23
Genetic Signatures Limited Appoints Karl Pechmann as Chief Operating Officer, Effective 26 June 2023	15/06/23
Genetic Signatures Appoints Interim CFO	21/03/23
Genetic Signatures Limited Announces Management Changes	20/03/23
C4X Discovery launches medicine platform on Parkinson's study results	22/02/23
Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23
Genetic Signatures Sees 16% Rise in Fiscal Q1 Sales	27/10/22
Genetic Signatures Says Study Shows Detection Kit Has 'Excellent Sensitivity and Specificity'	29/09/22
Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/08/22
Genetic Signatures Records 10% Decline in Fiscal Q4 Sales	27/07/22
Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit	26/07/22
Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director	13/05/22
Genetic Signatures Sales More than Double in Fiscal Q3	26/04/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Genetic Signatures Limited

Equities

GSS

AU000000GSS4

Other languages

Filters